A Non-Interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron [Peginterferon-alfa-2b] and Rebetol [ribavirin] Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE).

Trial Profile

A Non-Interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron [Peginterferon-alfa-2b] and Rebetol [ribavirin] Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PRACTICE
  • Sponsors Schering-Plough
  • Most Recent Events

    • 16 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Planned end date changed from 1 Sep 2010 to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top